Hair Loss with GLP-1 Peptides: What Research Shows About Telogen Effluvium

Hair loss is among the most frequently discussed side effects associated with GLP-1 receptor agonists. While gastrointestinal adverse events such as nausea and diarrhea dominate the clinical trial literature, users increasingly report noticeable hair shedding. Whether GLP-1 peptides directly cause hair loss or whether rapid weight loss is the actual trigger remains a subject of ongoing research.

This article summarizes the available clinical data on hair loss with Semaglutide, Tirzepatide and Retatrutide, and places the findings in the context of telogen effluvium.

What Is Telogen Effluvium?

Understanding hair loss with GLP-1 peptides requires a basic knowledge of the hair cycle. Each hair follicle passes through three phases:

Phase	Description	Duration	Proportion of Hair
Anagen	Growth phase	2-7 years	approx. 85-90%
Catagen	Transition phase	2-3 weeks	approx. 1-2%
Telogen	Resting phase	2-4 months	approx. 10-15%

Under normal conditions, approximately 85-90% of scalp hairs are in the anagen phase and only 10-15% in the telogen phase. In telogen effluvium (TE), this ratio shifts: a triggering event causes an abnormally high proportion of hairs to prematurely transition from the anagen to the telogen phase. After a latency period of typically 2-4 months, these hairs then fall out simultaneously, presenting as diffuse, non-scarring hair loss.

Telogen effluvium is not a disease in the classical sense but rather a physiological stress response of the body. Known triggers include:

Severe illness or surgery
High fever
Significant psychological stress
Hormonal changes (e.g., postpartum)
Nutritional deficiencies
Rapid, significant weight loss

The last point is of central importance in the discussion surrounding GLP-1 peptides.

Why Rapid Weight Loss Can Trigger Hair Loss

Rapid weight loss represents a form of metabolic stress for the body. Several mechanisms can contribute to telogen effluvium:

Caloric Deficit and Metabolic Stress

A severe caloric deficit signals a state of deprivation to the body. Since hair growth is not an essential survival function, it is among the first systems to be downregulated when resources are scarce. The body prioritizes vital organ functions over hair growth.

Protein Deficiency

GLP-1 agonists significantly reduce appetite. When overall food intake drops sharply, protein intake may become insufficient. Hair is composed of approximately 95% keratin, a structural protein. Without adequate amino acid supply, keratin synthesis is restricted, and hair follicles prematurely enter the telogen phase.

Micronutrient Deficiencies

Beyond protein, several micronutrients play important roles in the hair cycle:

Iron: Ferritin deficiency is one of the most common triggers for telogen effluvium, particularly in women
Zinc: Essential for cell division in the hair follicle
Biotin (Vitamin B7): Involved in keratin synthesis
Vitamin D: Modulates the hair cycle and follicle regeneration
Selenium: Antioxidant protection of hair follicles

With drastically reduced food intake, these micronutrients can quickly fall below critical thresholds.

Hormonal Changes

Weight loss affects hormone levels, particularly thyroid hormones, insulin, and sex hormones. Adipose tissue is an endocrine-active organ, and rapid reduction can lead to temporary hormonal imbalances that influence the hair cycle.

Clinical Trial Data

The available clinical trial data provide a differentiated picture of hair loss frequency across different GLP-1 peptides.

Semaglutide (STEP Trials)

In the STEP trials (Semaglutide Treatment Effect in People with Obesity), alopecia was systematically recorded as an adverse event:

STEP 1: Approximately 3% of participants on Semaglutide 2.4 mg reported hair loss, compared to 1% in the placebo group
Among participants with more than 20% weight loss, the rate was 5.3%, compared to 2.5% with less weight loss
A real-world analysis in the Journal of the American Academy of Dermatology (2024) found rates of 0.80-0.83% for telogen effluvium or non-scarring alopecia within six months of treatment initiation

A 2025 study (medRxiv) reported an adjusted hazard ratio of 2.08 (95% CI: 1.17-3.72) for hair loss in women on Semaglutide compared to Bupropion-Naltrexone. In men, the hazard ratio of 0.86 was not significantly elevated.

Tirzepatide (SURMOUNT Trials)

The SURMOUNT-1 trial for Tirzepatide showed higher rates:

5-6% of participants on Tirzepatide reported alopecia
In the placebo group, the rate was only 1%
The FDA prescribing information for Zepbound (Tirzepatide) lists alopecia as a known adverse reaction

Retatrutide (Phase 2 Trial)

Interestingly, hair loss was not listed as a common adverse event in the published Phase 2 trial for Retatrutide (NEJM, 2023). Alopecia was not a predefined endpoint, and the study focused primarily on gastrointestinal adverse events. It should be noted that Phase 2 trials with 338 participants have limited statistical power to detect less common adverse events. Phase 3 data are still pending.

Comparison Table: Hair Loss Rates in Clinical Trials

Peptide	Trial	Alopecia Rate (Active)	Alopecia Rate (Placebo)	Max. Weight Loss
Semaglutide 2.4 mg	STEP 1	~3%	~1%	~15%
Tirzepatide	SURMOUNT-1	5-6%	~1%	~21%
Retatrutide	Phase 2	Not prominently reported	-	~24%

A notable pattern: the alopecia rate appears to correlate with the degree of weight loss. Tirzepatide, which produces greater weight loss than Semaglutide, also shows higher hair loss rates. The exception of Retatrutide may be attributable to the limited study size or different reporting methods.

Is It the Peptide or the Weight Loss?

This question is central to understanding causality. Several observations suggest that weight loss, rather than the peptide itself, causes the hair loss:

Comparison with Bariatric Surgery

Bariatric procedures (gastric bypass, sleeve gastrectomy) also cause rapid weight loss, entirely without GLP-1 peptides. Hair loss rates are significantly higher:

Over 50% of patients after bariatric surgery report hair loss
Telogen effluvium typically occurs 3-6 months after the procedure
The causes are identical: caloric deficit, malabsorption, nutritional deficiencies

Weight Loss Method	Alopecia Rate	Mechanism
Semaglutide 2.4 mg	3-5%	Appetite reduction, caloric deficit
Tirzepatide	5-6%	Appetite reduction, caloric deficit
Bariatric surgery	>50%	Malabsorption + caloric deficit
Calorie-restrictive diets	10-20% (estimated)	Caloric deficit

The significantly higher rates after bariatric surgery, where no GLP-1 peptide is involved, support the hypothesis that weight loss is the primary trigger.

FAERS Data

A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database from 2022 to 2023 (PubMed, 2024) found elevated alopecia reports for both Semaglutide and Tirzepatide. However, such pharmacovigilance analyses cannot establish causality, as they are influenced by reporting bias and confounding factors, among other limitations.

Dose-Response Relationship with Weight Loss

The Wegovy trial data show a clear correlation: participants with more than 20% weight loss reported hair loss twice as frequently (5.3%) as participants with less weight loss (2.5%). This supports weight loss as the driving factor.

Risk Factors for Hair Loss with GLP-1 Peptides

Not all individuals using GLP-1 peptides develop hair loss. Certain risk factors increase the likelihood:

Rate of Weight Loss

The faster the weight loss, the higher the risk of telogen effluvium. Loss of more than 1 kg per week over an extended period is considered a risk factor.

Sex

The available data suggest that women carry a higher risk. The medRxiv study cited above found a significantly elevated hazard ratio only in women (HR 2.08), not in men (HR 0.86). Possible reasons include lower iron stores and greater sensitivity to hormonal changes.

Pre-existing Nutritional Deficiencies

Low ferritin levels (iron stores below 40 ng/mL)
Zinc deficiency
Vitamin D deficiency
Protein deficiency with an already unbalanced diet

Additional Factors

History of telogen effluvium
Concurrent psychological or physical stress
Thyroid dysfunction
High baseline weight (greater absolute weight loss)

Considerations for Researchers

For the design of research protocols involving GLP-1 peptides, several considerations emerge from the available data:

Ensuring Protein Intake

Adequate protein intake is the most important modifiable factor. Current recommendations from bariatric research suggest:

At least 60-80 g of protein per day, even with reduced total caloric intake
1.2-1.5 g protein per kg of target weight as a guideline
Prefer high-quality protein sources with complete amino acid profiles

Micronutrient Monitoring

Regular monitoring of ferritin, zinc, vitamin D, vitamin B12, and folate
Supplementation for documented deficiencies
Special attention for women of childbearing age (frequently low iron stores)

Rate of Weight Loss

A moderate rate of weight loss may reduce the risk of telogen effluvium. In research protocols, this can be influenced through peptide dose titration.

Documentation

Since alopecia is not a primary endpoint in many trials, it may be underreported. Systematic assessment of hair loss symptoms in future study protocols would be desirable.

Reversibility: Telogen Effluvium Is Temporary

A central point that is often underemphasized in public discussion: telogen effluvium is typically fully reversible. After the triggering stressor is removed, the hair cycle typically normalizes within 3-6 months.

The timeline:

Months 1-3 after onset of weight loss: Hair follicles prematurely enter the telogen phase (no visible hair loss yet)
Months 3-6: Visible hair loss as telogen hairs are shed
Months 6-9: Stabilization if the trigger is controlled
Months 9-12: New hair growth becomes visible, hair density normalizes

Important: This applies as long as the triggering factor is temporary. With persistently inadequate nutrition or chronic nutritional deficiencies, telogen effluvium can transition to a chronic form.

Differentiation: Telogen Effluvium vs. Androgenetic Alopecia

For correct classification of hair loss with GLP-1 peptides, distinguishing it from other forms of alopecia is important, particularly androgenetic alopecia (AGA):

Feature	Telogen Effluvium	Androgenetic Alopecia
Pattern	Diffuse, evenly distributed across the scalp	Typical pattern (receding hairline, crown thinning in men; part widening in women)
Onset	Acute, 2-4 months after trigger	Gradual, over months to years
Reversibility	Typically fully reversible	Progressive without treatment
Cause	Metabolic/physical stress	Genetic, hormonal (DHT-mediated)
Hair density	Temporarily reduced	Permanently diminished at affected sites
Pull test	Positive (>10% telogen hairs)	Usually negative

It is possible that GLP-1-mediated weight loss triggers telogen effluvium in individuals who simultaneously have a genetic predisposition for androgenetic alopecia. In such cases, the diffuse hair loss can unmask a previously unnoticed AGA.

Conclusion

The available research data paint a differentiated picture: hair loss with GLP-1 peptides such as Semaglutide, Tirzepatide and Retatrutide is a real phenomenon documented in clinical trials at rates of 3-6%. However, the evidence suggests that rapid weight loss and the associated metabolic changes represent the primary trigger, not the peptides themselves.

Telogen effluvium, the most common form of hair loss in this context, is a physiological stress response and typically fully reversible within 6-12 months. The significantly higher hair loss rates after bariatric surgery (over 50%) support the hypothesis that the extent and speed of weight loss are the decisive variables.

For research, this means: systematic assessment of alopecia as an endpoint, together with documentation of nutritional status and rate of weight loss, is desirable in future studies with GLP-1 peptides. Only then can the relationship between peptide effect, weight loss, and hair health be further elucidated.

This article is for scientific research information purposes only. All cited study data originate from publicly available publications and databases.